Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 5/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | TBK1 | Q9UHD2 | 14/20 | 0.39 |
| ▸ | JAK2 | O60674 | 12/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21707007 | 0.77 | MAPT (0.54) | SYK | |
| SCHEMBL25401906 | 0.72 | MEN1 (0.48) | EGFR | |
| SCHEMBL17054935 | 0.70 | MAPT (0.51) | EGFR | |
| SCHEMBL21707239 | 0.70 | HPGD (0.49) | — | |
| SCHEMBL17630727 | 0.69 | EGFR (0.47) | BTKEGFRTBK1JAK2 | |
| SCHEMBL17665174 | 0.69 | SLC18A3 (0.42) | BTKEGFR | |
| SCHEMBL21679536 | 0.68 | SLC18A3 (0.41) | BTKEGFRTBK1JAK2 | |
| SCHEMBL23865969 | 0.68 | SLC18A3 (0.44) | BTKEGFRTBK1JAK2 | |
| SCHEMBL21679537 | 0.68 | SLC18A3 (0.41) | BTKEGFRTBK1JAK2 | |
| SCHEMBL22296226 | 0.66 | SLC18A3 (0.39) | BTKEGFRTBK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174254-B2 | Aniline-substituted 1,2-dihydropyrrol[3,4-C]pyridin/pyrimidin-3-one derivative and use thereof | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-11-16 | — | — | US | disclosed |
| US-20200048248-A1 | ANILINE-SUBSTITUTED 1,2-DIHYDROPYRROL[3,4-C]PYRIDIN/PYRIMIDIN-3-ONE DERIVATIVE AND USE THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048248-A1 | ANILINE-SUBSTITUTED 1,2-DIHYDROPYRROL[3,4-C]PYRIDIN/PYRIMIDIN-3-ONE DERIVATIVE AND USE THEREOF | DPYD, ACR, QDPR | BTK 1484/4885EGFR 4038/4885TBK1 3217/4885 |
| US-11174254-B2 | Aniline-substituted 1,2-dihydropyrrol[3,4-C]pyridin/pyrimidin-3-one derivative and use thereof | DPYD, ACR, QDPR | BTK 1484/4885EGFR 4038/4885TBK1 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.